Mucopolysaccharidosis type II or Hunter’s syndrome is a rare, X-linked genetic lysosomal storage disorder, which results in multiorgan dysfunction and accumulation of glycosaminoglycans in various ...

Medipal Holdings Corporation and JCR Pharmaceuticals Co Ltd announced that the European Commission (EC) has granted orphan drug designation to JR-446, an investigational drug for the treatment of ...

JCR Pharmaceuticals Co, a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured ...

DelveInsight’s, “Mucopolysaccharidosis Type I Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucopolysaccharidosis Type I pipeline landscape.

PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has ...

PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has ...

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment PR Newswire PARAMUS, N.J., May 14, 2025 ...

Mucopolysaccharidosis Type I Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, ...

NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR) of ...